Page last updated: 2024-11-05

vigabatrin and Hepatic Encephalopathy

vigabatrin has been researched along with Hepatic Encephalopathy in 1 studies

Hepatic Encephalopathy: A syndrome characterized by central nervous system dysfunction in association with LIVER FAILURE, including portal-systemic shunts. Clinical features include lethargy and CONFUSION (frequently progressing to COMA); ASTERIXIS; NYSTAGMUS, PATHOLOGIC; brisk oculovestibular reflexes; decorticate and decerebrate posturing; MUSCLE SPASTICITY; and bilateral extensor plantar reflexes (see REFLEX, BABINSKI). ELECTROENCEPHALOGRAPHY may demonstrate triphasic waves. (From Adams et al., Principles of Neurology, 6th ed, pp1117-20; Plum & Posner, Diagnosis of Stupor and Coma, 3rd ed, p222-5)

Research Excerpts

ExcerptRelevanceReference
"Based on the reversal of hepatic encephalopathy in animal models with administration of specific benzodiazepine receptor antagonists, it has been postulated that this syndrome may be mediated by an endogenous benzodiazepine-like compound."1.28Evidence for the presence of a benzodiazepine receptor binding substance in cerebrospinal fluid of a rabbit model of hepatic encephalopathy. ( Jones, EA; Kaminsky-Russ, K; Martin, JV; Mendelson, WB; Mullen, KD, 1989)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Mullen, KD1
Martin, JV1
Mendelson, WB1
Kaminsky-Russ, K1
Jones, EA1

Other Studies

1 other study available for vigabatrin and Hepatic Encephalopathy

ArticleYear
Evidence for the presence of a benzodiazepine receptor binding substance in cerebrospinal fluid of a rabbit model of hepatic encephalopathy.
    Metabolic brain disease, 1989, Volume: 4, Issue:4

    Topics: Aminocaproates; Animals; Binding, Competitive; Flumazenil; GABA-A Receptor Antagonists; Galactosamin

1989